• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Oncology

Duration-based lung cancer screening may reduce racial disparities in eligibility

byAdrian WongandMichaela Dowling
December 15, 2025
in Oncology, Public Health
Reading Time: 3 mins read
Rapid growth of medical artificial intelligence technology usage identified from insurance claims analysis, yet major barriers to widespread adoption remain
Share on FacebookShare on Twitter

1. In this prospective cohort study, duration-based criteria reduced racial disparities in lung cancer screening eligibility, increasing access for minority groups compared with current US guidelines.
2. Duration-based criteria increased six-year lung cancer detection sensitivity across all racial groups, although specificity declined.

Evidence Rating Level: 2 (Good)

Study Rundown: The 2021 US Preventive Services Task Force (USPSTF-2021) lung cancer screening guidelines lowered the minimum cumulative smoking exposure from 30 to 20 pack-years and the minimum screening age from 55 to 50 years to increase screening uptake and reduce racial disparities. However, evidence suggests that smoking duration, rather than pack-years, may better predict lung cancer risk in some populations. As a result, smoking duration–based and risk-based screening criteria have been proposed. This study compared smoking duration–based screening with USPSTF-2021 guidelines and assessed duration-based screening relative to a risk-based approach. Using a 30-year smoking duration threshold (duration-based-30), eligibility rates were most comparable to USPSTF-2021 while reducing inter-racial disparities. Sensitivity for detecting lung cancer within six years increased across all racial groups, though specificity decreased. Comparing duration-based-30 with a 6-year PLCOm2012 threshold of 1.1% (risk-based-1.1%) revealed that African Americans had higher eligibility than Whites, widening the gap in their favor. For other racial groups, eligibility increased in favor of Whites, particularly widening the gap with Latinos. Overall, the risk-based approach improved sensitivity and specificity compared with duration-based-30, though sensitivity was lower among Latino individuals. Limitations include a geographically restricted cohort, enrollment in the 1990s, and inability to assess overdiagnosis. Nonetheless, the findings suggest that smoking duration–based criteria may reduce racial disparities in lung cancer screening relative to current guidelines while enhancing sensitivity across racial and ethnic groups.

Click to read this study in AIM

Relevant Reading: Pack-Year Smoking History: An Inadequate and Biased Measure to Determine Lung Cancer Screening Eligibility

In-Depth [prospective study]: This prospective cohort study compared smoking duration-based criteria with USPSTF-2021 guidelines for lung cancer screening and further assessed duration-based versus risk-based screening using the PLCOm2012update model. The cohort was drawn from the Multiethnic Cohort Study, which enrolled 214,862 adults aged 45-75 years in California and Hawaii from 1993 to 1996, including African American, Japanese American, Latino, Native Hawaiian/Other Pacific Islander, and White participants. After excluding those with missing smoking or risk factor data, 105,261 participants were analyzed. The population was 57.0% male, mean age 59.8 years, with 29.6% current smokers and 70.4% former smokers; mean pack-years and smoking duration were 18.4 and 22.5 years, respectively. Within six years, 1.4% (n = 1464) developed lung cancer. Under USPSTF-2021, 24% of participants were eligible for screening, with eligibility highest among Whites (30.2%) and lowest among Latinos (15.7%). Smoking duration thresholds of 10, 20, 30, and 40 years yielded overall eligibility rates of 48.6%, 40.5%, 27.5%, and 12.8%, respectively; the 30-year threshold (duration-based-30) most closely matched USPSTF-2021 and was used in subsequent analyses. Duration-based-30 narrowed inter-racial eligibility gaps: Whites (28.8%), African Americans (30.4%), Latinos (25.1%), Native Hawaiians (26.1%), and Japanese Americans (26.5%). Sensitivity increased across all groups using the duration-based-30 compared to USPSTF-2021 (66.1% vs. 57.7%), particularly in African Americans (60.9% vs. 44.0%) and Latinos (69.8% vs. 53.5%), though overall specificity decreased (73.0% vs. 76.5%). Compared with risk-based criteria, African Americans had higher eligibility than Whites (39.3% vs. 31.3%), whereas eligibility gaps for other minority groups widened in favor of Whites, particularly among Latinos (14.4% vs. 31.3%). Risk-based criteria improved overall sensitivity (72.0% vs. 66.1%) and specificity (73.1% vs. 73.0%), with sensitivity gains in African Americans, Japanese Americans, Native Hawaiians, and Whites, but lower sensitivity in Latinos (59.7% vs. 69.8%) with higher specificity. Overall, duration-based criteria may reduce racial disparities in screening and improve sensitivity among minority populations compared with existing USPSTF-2021 guidelines.

RELATED REPORTS

Lung cancer screening models show variable performance across populations

Positive lung cancer screens frequently receive suboptimal follow-up

Age-based screening for lung cancer may be more cost-effective and improve detection compared to current screening criteria in the United States

Image: PD

©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: lung cancer screening
Previous Post

Drug-related pressure ulcers may be characterised by medication-related characteristics such as polypharmacy and medication changes rather than baseline immobility

Next Post

Positive lung cancer screens frequently receive suboptimal follow-up

RelatedReports

Thoracic radiotherapy improves survival in small-cell lung cancer patients
Oncology

Lung cancer screening models show variable performance across populations

June 29, 2026
Pulmonary MRI with ultrashort echo time is comparable to pulmonary CT
Oncology

Positive lung cancer screens frequently receive suboptimal follow-up

December 15, 2025
Severity of emphysema on pulmonary CT may predict lung cancer location
Chronic Disease

Age-based screening for lung cancer may be more cost-effective and improve detection compared to current screening criteria in the United States

January 13, 2026
Cancer to surpass heart disease as leading cause of death in the U.S. for higher-income persons
Chronic Disease

Low-Dose CT for Lung Cancer Screening in a High-Risk Population

March 31, 2025
Next Post
Pulmonary MRI with ultrashort echo time is comparable to pulmonary CT

Positive lung cancer screens frequently receive suboptimal follow-up

Dietary variety linked to greater increase in childhood BMI

Reducing saturated fat decreases mortality in high-risk individuals

Parental nonmedical prescription opioid use linked to adolescent use

Bisphosphonates may reduce short-term pain in complex regional pain syndrome 

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • A long-term gonadotropin-releasing hormone agonist protocol may be associated with increased positive pregnancy outcomes in women with endometriosis undergoing frozen embryo transfer
  • A machine-learning diet score identifies eating patterns associated with lower aging-related mortality
  • Deep-learning model achieved high diagnostic performance for detecting cardiac enlargement using electrocardiograms
License Content
Terms of Use | Disclaimer
Cookie Policy
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.